



Background 1-4

- The potency of cannabis products is based on the percentage of delta-9-tetrahydrocannabinol (THC), the primary psychoactive ingredient of cannabis.
- Marijuana use is now 20% more prevalent among residents of states where it is legal for recreational use than in other states.
- The average potency of cannabis has increased dramatically throughout the last few decades in the United States after legalization.
- The majority of states that have legalized marijuana had THC content that was far above 15%, 19%-21% in some states.

Methods

PubMed and Web of Science were utilized for a narrative review focusing on THC potency and its adverse effects till January 2023.

Conclusion

- Given the evidence of harmful effects associated with high-potency cannabis, there is a need for reevaluation of cannabis product potency regulation following its legalization in the US.
- States considering future legalization should prioritize understanding the implications of increased consumption of higher potency cannabis


References

- Campos, Alline C., et al. "Cannabidiol, neuroprotection and neuropsychiatric disorders." Pharmacological research 112 (2016): 119-127.
- Zellers, Stephanie M., et al. "Impacts of recreational cannabis legalization on cannabis use: a longitudinal discordant twin study." Addiction 118.1 (2023): 110-118.
- Mehmedic, Zlatko, et al. "Potency trends of Δ9-THC and other cannabinoids in confiscated cannabis preparations from 1993 to 2008." Journal of forensic sciences 55.5 (2010): 1209-1217.
- Cash, Mary Catherine, et al. "Mapping cannabis potency in medical and recreational programs in the United States." PloS one 15.3 (2020): e0230167.
- Laumon, Bernard, et al. "Cannabis intoxication and fatal road crashes in France: population based case-control study." Bmj 331.7529 (2005): 1371.
- Brubacher, Jeffrey R., et al. "Cannabis use as a risk factor for causing motor vehicle crashes: a prospective study." Addiction 114.9 (2019): 1616-1626.
- Di Forti, Marta, et al. "Daily use, especially of high-potency cannabis, drives the earlier onset of psychosis in cannabis users." Schizophrenia bulletin 40.6 (2014): 1509-1517. Kim, Howard S., et al. "Cyclic vomiting presentations following marijuana liberalization in Colorado." Academic Emergency Medicine 22.6 (2015): 694-699.
- Gobbi, Gabriella, et al. "Association of cannabis use in adolescence and risk of depression, anxiety, and suicidality in young adulthood: a systematic review and meta-analysis." JAMA psychiatry 76.4 (2019): 426-434.

Limiting the Potency of Delta-9-Tetrahydrocannabinol (THC) in Cannabis **Products: What Policymakers Need to Know**

N M Mahmudul Alam Bhuiya, MPharm; Akhila Yerubandi, PharmD; Henry N Young, PhD, FAPhA; Lorenzo A Villa Zapata, PhD, PharmD; Randall L. Tackett, PhD University of Georgia, College of Pharmacy, Athens, GA

This study examined the impact of elevated levels of tetrahydrocannabinol (THC) in cannabis products on the development of psychosis, cognitive function, driving impairment, hyperemesis, and pregnancy outcomes, due to the growing accessibility and potency of these products following legalization in the United States.



- symptoms compared to noncannabis users
- Daily users of high-potency times more likely to have a users.

Objectives



